t
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Ms E Walmsley |
||||
|
b) |
Position/status |
Chief Executive Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2022-10-10 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr I Mackay |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.2260 |
1,917.266 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2022-10-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
On October 10, 2022, GSK plc's Chief Executive Officer, Ms E Walmsley, and Chief Financial Officer, Mr I Mackay, each acquired Ordinary Shares of 31 ¼ pence on the London Stock Exchange at a price of £13.2260 per share. These acquisitions, totalling 7,963.086 shares for Ms Walmsley and 1,917.266 shares for Mr Mackay, resulted from the re-investment of dividends from shares held in the Company's Performance Share Plan.
| Date | 12 Oct 2022 |
| Time | 11:42:12 |
| Category | Director/PDMR dealings |
| ID | 6613C |